All-oral phase II trial of ACH 3422 in combination with ACH 3102 in patients with hepatitis C
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2015
Price : $35 *
At a glance
- Drugs ACH 3422 (Primary) ; Odalasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 05 Mar 2015 SVR4 results are expected in the second half of 2015, according to an Achillion media release.
- 05 Mar 2015 Planned initiation date changed from 1 Dec 2014 to 1 Jun 2015, according to an Achillion media release.
- 15 Aug 2014 This trial is expected to be initiated before the end of 2014, according to an Achillion media release.